17:35 , Sep 28, 2018 |  BC Week In Review  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Sept. 26, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400...
20:07 , Sep 26, 2018 |  BC Extra  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Wednesday, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400 million...
20:30 , Jun 23, 2017 |  BC Week In Review  |  Financial News

Autoimmune play Syntimmune raises $50M

On June 21, autoimmune disease company Syntimmune Inc. (New York, N.Y.) raised $50 million a series B round led by existing investor Apple Tree Partners with a $48 million investment. Existing investors Partners Innovation Fund,...
17:47 , Jun 21, 2017 |  BC Extra  |  Financial News

Autoimmune play Syntimmune raises $50M

Autoimmune disease company Syntimmune Inc. (New York, N.Y.) raised $50 million in a series B round. Existing investor Apple Tree Partners invested $48 million to lead the round. Also participating were existing investors Partners Innovation...
07:00 , Apr 22, 2002 |  BioCentury  |  Finance

Ebb & Flow

Investors cleaning the mud off their boots from biotech's first quarter disasters breathed a sigh of relief after...
07:00 , Apr 16, 2002 |  BC Extra  |  Financial News

Syntonix raises $35.8 million

Syntonix Pharmaceuticals raised $35.8 million in a series B financing led by Bay City Capital and Alta Partners. Other investors included A.M. Pappas; Global Biomedical Partners; AFB Fund; Venrock Associates; BancBoston Ventures; Merrill Lynch Ventures;...